Search results for "PHARMACOLOGY"

showing 10 items of 8885 documents

Enhanced emergence of antibiotic-resistant pathogenic bacteria after in vitro induction with cancer chemotherapy drugs.

2019

International audience; BACKGROUND:Infections with antibiotic-resistant pathogens in cancer patients are a leading cause of mortality. Cancer patients are treated with compounds that can damage bacterial DNA, potentially triggering the SOS response, which in turn enhances the bacterial mutation rate. Antibiotic resistance readily occurs after mutation of bacterial core genes. Thus, we tested whether cancer chemotherapy drugs enhance the emergence of resistant mutants in commensal bacteria.METHODS:Induction of the SOS response was tested after the incubation of Escherichia coli biosensors with 39 chemotherapeutic drugs at therapeutic concentrations. The mutation frequency was assessed after …

0301 basic medicineMicrobiology (medical)Staphylococcus aureusmedicine.drug_class030106 microbiologyAntibioticsAntineoplastic AgentsDrug resistanceMicrobial Sensitivity TestsBiologymedicine.disease_causeMicrobiology03 medical and health sciencesSOS Response (Genetics)0302 clinical medicineAntibiotic resistanceDrug Resistance BacterialEnterobacter cloacaemedicineHumansPharmacology (medical)030212 general & internal medicineMutation frequencySOS responseSOS Response GeneticsPharmacologyPathogenic bacteriaChemotherapy regimen3. Good healthAnti-Bacterial Agents[SDV.MP]Life Sciences [q-bio]/Microbiology and ParasitologyInfectious DiseasesPseudomonas aeruginosaThe Journal of antimicrobial chemotherapy
researchProduct

New Synthetic Nitro-Pyrrolomycins as Promising Antibacterial and Anticancer Agents

2020

: Pyrrolomycins (PMs) are polyhalogenated antibiotics known as powerful biologically active compounds, yet featuring high cytotoxicity. The present study reports the antibacterial and antitumoral properties of new chemically synthesized PMs, where the three positions of the pyrrolic nucleus were replaced by nitro groups, aiming to reduce their cytotoxicity while maintaining or even enhancing the biological activity. Indeed, the presence of the nitro substituent in diverse positions of the pyrrole determined an improvement of the minimal bactericidal concentration (MBC) against Gram-positive (i.e., Staphylococcus aureus) or -negative (i.e., Pseudomonas aeruginosa) pathogen strains as compare…

0301 basic medicineMicrobiology (medical)Staphylococcus aureusmedicine.drug_classAntibioticspyrrolomycinmedicine.disease_causeSettore BIO/19 - Microbiologia Generale01 natural sciencesBiochemistryMicrobiologypyrrolic nucleusHCT116Article03 medical and health sciencesantibacterial activityMCF 7medicinePharmacology (medical)General Pharmacology Toxicology and PharmaceuticsSettore BIO/06 - Anatomia Comparata E CitologiaCytotoxicityheterocyclesMinimum bactericidal concentrationantitumoral activity010405 organic chemistryChemistryPseudomonas aeruginosalcsh:RM1-950MCF7Biological activitySettore CHIM/08 - Chimica Farmaceutica0104 chemical scienceslcsh:Therapeutics. Pharmacology030104 developmental biologyInfectious DiseasesMCF-7BiochemistryStaphylococcus aureusPseudomonas aeruginosaNitroAntibiotics
researchProduct

Gut Microbiome Associates With Lipid-Lowering Effect of Rosuvastatin in Vivo

2018

Source at https://doi.org/10.3389/fmicb.2018.00530 . Background: Statin has been widely used to treat hyperlipidemia because of its high potency in decreasing cholesterol levels. The present study aimed to examine the lipid-lowering effect of rosuvastatin and the composition, diversity and species abundance of gut microbiome in association with rosuvastatin efficacy. TRIAL REGISTRATION: ChiCTR-ORC-17013212 at the First Affiliated Hospital of Dalian Medical University, November 2, 2017. Results:Totally 64 patients with hyperlipidemia were treated with 10 mg/day of rosuvastatin for 4-8 weeks. Blood lipid indicators triglycerides (TG), total cholesterol (TC), high density lipoprotein (HDL), lo…

0301 basic medicineMicrobiology (medical)Statinmedicine.drug_classlcsh:QR1-502PhysiologyBlood lipidsgut microbiomeBiologyGut floraMicrobiologylcsh:Microbiology03 medical and health scienceschemistry.chemical_compoundHigh-density lipoproteinHyperlipidemiamedicinehyperlipidemiaRosuvastatinVDP::Medical disciplines: 700::Clinical medical disciplines: 750::Cardiology: 771VDP::Medisinske Fag: 700::Klinisk medisinske fag: 750::Kardiologi: 771CholesterolVDP::Medical disciplines: 700::Basic medical dental and veterinary science disciplines: 710::Pharmacology: 728nutritional and metabolic diseasesFusobacteriaVDP::Medical disciplines: 700::Basic medical dental and veterinary science disciplines: 710::Medical microbiology: 715medicine.diseasebiology.organism_classification16S rRNA sequencing030104 developmental biologychemistryVDP::Medisinske Fag: 700::Basale medisinske odontologiske og veterinærmedisinske fag: 710::Medisinsk mikrobiologi: 715VDP::Medisinske Fag: 700::Basale medisinske odontologiske og veterinærmedisinske fag: 710::Farmakologi: 728lipids (amino acids peptides and proteins)hypolipidemic effectrosuvastatinmedicine.drugFrontiers in Microbiology
researchProduct

Performance of disc diffusion, MIC gradient tests and Vitek 2 for ceftolozane/tazobactam and ceftazidime/avibactam susceptibility testing of Pseudomo…

2021

AbstractObjectivesTo assess performance of disc diffusion, gradient tests and Vitek 2 system to determine the susceptibility of clinical Pseudomonas aeruginosa strains to ceftolozane/tazobactam (C/T) and ceftazidime/avibactam (CZA).MethodsTwo-hundred non-duplicate P. aeruginosa strains isolated by 47 French medical laboratories were selected to cover a wide range of C/T and CZA MICs. Performance of C/T disc (30/10 μg, Bio-Rad), CZA discs (10/4 μg) (Thermo Fisher and Bio-Rad), C/T and CZA gradient tests (Etest, BioMérieux; MIC Test Strip, Liofilchem), and AST-XN12 card of Vitek 2 system (BioMérieux) were compared with a broth microdilution (BMD) method (Thermo Fisher). MIC and disc results w…

0301 basic medicineMicrobiology (medical)TazobactamAvibactam030106 microbiologyCeftazidimeMicrobial Sensitivity Testsmedicine.disease_causeTazobactamCeftazidime03 medical and health scienceschemistry.chemical_compound0302 clinical medicinemedicineHumansPharmacology (medical)Pseudomonas Infections030212 general & internal medicineEtestPharmacologyChromatographyPseudomonas aeruginosaChemistryBroth microdilutionCeftazidime/avibactamAnti-Bacterial AgentsCephalosporinsDrug CombinationsInfectious Diseases[SDV.MP]Life Sciences [q-bio]/Microbiology and ParasitologyPseudomonas aeruginosaCeftolozaneAzabicyclo Compoundsmedicine.drug
researchProduct

Are moxifloxacin and levofloxacin equally effective to treat XDR tuberculosis?

2017

International audience; Background: Moxifloxacin retains partial activity against some fluoroquinolone-resistant mutants of Mycobacterium tuberculosis. Levofloxacin is presumed to be as active as moxifloxacin against drug-susceptible tuberculosis and to have a better safety profile.Objectives: To compare the in vivo activity of levofloxacin and moxifloxacin against M. tuberculosis strains with various levels of fluoroquinolone resistance.Methods: BALB/c mice were intravenously infected with 106M. tuberculosis H37Rv and three isogenic mutants: GyrA A90V, GyrB E540A and GyrB A543V. Treatment with 50 or 100 mg/kg levofloxacin and 60 or 66 mg/kg moxifloxacin was given orally every 6 h, for 4 we…

0301 basic medicineMicrobiology (medical)Tuberculosis[SDV.SP.MED] Life Sciences [q-bio]/Pharmaceutical sciences/MedicationmiceExtensively Drug-Resistant Tuberculosis030106 microbiologyMicrobial Sensitivity TestsMicrobiologyMycobacterium tuberculosis03 medical and health sciences0302 clinical medicine[SDV.SP.MED]Life Sciences [q-bio]/Pharmaceutical sciences/MedicationLevofloxacinMoxifloxacinIn vivo[SDV.MHEP.MI]Life Sciences [q-bio]/Human health and pathology/Infectious diseasesmedicineAnimalsPharmacology (medical)heterocyclic compounds030212 general & internal medicinePharmacologyMice Inbred BALB ClevofloxacinbiologyChemistry[ SDV.SP.MED ] Life Sciences [q-bio]/Pharmaceutical sciences/MedicationExtensively drug-resistant tuberculosisMycobacterium tuberculosisbiochemical phenomena metabolism and nutritionmedicine.diseasebiology.organism_classificationbacterial infections and mycosesFluoroquinolone resistanceAnti-Bacterial Agents3. Good health[ SDV.MHEP.MI ] Life Sciences [q-bio]/Human health and pathology/Infectious diseasesDisease Models AnimalSafety profileTreatment OutcomeInfectious Diseasestuberculosis[SDV.MHEP.MI] Life Sciences [q-bio]/Human health and pathology/Infectious diseasesbacteriamoxifloxacinFluoroquinolonesmedicine.drug
researchProduct

Resistance to third-generation cephalosporins in Escherichia coli in the French community: The times they are a-changin'?

2020

Since the early 2000s, Escherichia coli resistance to third-generation cephalosporins (3GCs) has been increasing in all European countries, mainly due to the spread of extended spectrum β-lactamases (ESBLs). Here we present a retrospective study that combines resistance of E. coli to 3GCs and quinolones with data on antibiotic use in the community in a region of Northeastern France.Since 2012, an observational surveillance of antimicrobial resistance and antibiotic use in the community was conducted: data on antimicrobial resistance in E. coli isolates were collected from 11 private laboratories, and consumption data were collected from the three main healthcare insurances.A significant dec…

0301 basic medicineMicrobiology (medical)Veterinary medicinemedicine.drug_classeducationResistance030106 microbiologyCephalosporinAntibioticsContext (language use)Microbial Sensitivity TestsQuinolonesmedicine.disease_causebeta-LactamasesThird generation cephalosporins03 medical and health sciencesNalidixic Acid0302 clinical medicineAntibiotic resistanceCiprofloxacinDrug Resistance BacterialOutpatientsmedicineEscherichia coliPrevalenceHumansPharmacology (medical)030212 general & internal medicineAntibiotic useEscherichia coliComputingMilieux_MISCELLANEOUSEscherichia coli InfectionsRetrospective StudiesResistance (ecology)business.industryThird-generation cephalosporinsGeneral Medicine3. Good healthAnti-Bacterial AgentsCephalosporins[SDV.MP]Life Sciences [q-bio]/Microbiology and ParasitologyInfectious Diseases[SDE]Environmental SciencesFrancebusinessInternational journal of antimicrobial agents
researchProduct

Occurrence and Antimicrobial Resistance of Arcobacter spp. Recovered from Aquatic Environments

2021

Arcobacter spp. are emerging waterborne and foodborne zoonotic pathogens responsible for gastroenteritis in humans. In this work, we evaluated the occurrence and the antimicrobial resistance profile of Arcobacter isolates recovered from different aquatic sources. Besides, we searched for Arcobacter spp. in seaweeds and the corresponding seawater samples. Bacteriological and molecular methods applied to 100 samples led to the isolation of 28 Arcobacter isolates from 27 samples. The highest prevalence was detected in rivers followed by artificial ponds, streams, well waters, and spring waters. Seaweeds contained a higher percentage of Arcobacter than the corresponding seawater samples. The is…

0301 basic medicineMicrobiology (medical)Water samplesVeterinary medicineAntibiotic susceptibilityArcobacter cryaerophilusTetWTetracyclinemedicine.drug_class030106 microbiologyAntibioticsTetOBiochemistryMicrobiologyArticle03 medical and health sciencesAntibiotic resistancemedicinePharmacology (medical)General Pharmacology Toxicology and PharmaceuticsbiologyAquatic ecosystemlcsh:RM1-950Arcobacter butzleri<i>Arcobacter butzleri</i>Multiplex PCRbiology.organism_classificationIsolation (microbiology)Arcobacter butzlerilcsh:Therapeutics. Pharmacology030104 developmental biologyInfectious DiseasesArcobacter<i>tetO</i><i>tetW</i>medicine.drugAntibiotics
researchProduct

Is Caretta Caretta a Carrier of Antibiotic Resistance in the Mediterranean Sea?

2020

Sea turtles can be considered a sentinel species for monitoring the health of marine ecosystems, acting, at the same time, as a carrier of microorganisms. Indeed, sea turtles can acquire the microbiota from their reproductive sites and feeding, contributing to the diffusion of antibiotic-resistant strains to uncontaminated environments. This study aims to unveil the presence of antibiotic-resistant bacteria in (i) loggerhead sea turtles stranded along the coast of Sicily (Mediterranean Sea), (ii) unhatched and/or hatched eggs, (iii) sand from the turtles&rsquo

0301 basic medicineMicrobiology (medical)antibiotic resistance030106 microbiologyZoologyheavy metal resistanceIntegronAntibiotic resistance Caretta caretta Mediterranean SeaBiochemistryMicrobiologyLoggerhead sea turtleArticleantimicrobials03 medical and health sciencesAntibiotic resistanceMediterranean seacaretta carettamedicineMediterranean SeaPharmacology (medical)Marine ecosystemGeneral Pharmacology Toxicology and Pharmaceuticsbiologymobile elementfungilcsh:RM1-950<i>caretta caretta</i>biology.organism_classificationloggerhead sea turtle030104 developmental biologyInfectious Diseaseslcsh:Therapeutics. PharmacologyAeromonasbiology.proteinColistinSeawatermedicine.drugAntibiotics
researchProduct

Comparison of Antibiotic Resistance Profile and Biofilm Production of Staphylococcus aureus Isolates Derived from Human Specimens and Animal-Derived …

2019

Background: The diffusion of antimicrobial resistance is a significant concern for public health worldwide. Staphylococcus aureus represents a paradigm microorganism for antibiotic resistance in that resistant strains appear within a decade after the introduction of new antibiotics. Methods: Fourteen S. aureus isolates from human specimens and twenty-one from samples of animal origin, were compared for their antimicrobial resistance and biofilm capability. In addition, they were characterized at the molecular level to detect the antimicrobial resistance mecA gene and genes related with enterotoxin, toxin, and biofilm production. Results: Both phenotypic and molecular analysis showed main di…

0301 basic medicineMicrobiology (medical)antibiotic resistancemedicine.drug_class030106 microbiologyAntibiotics<i>Staphylococcus aureus</i>VirulenceMRSAEnterotoxinBiologymedicine.disease_causeBiochemistryMicrobiologyMicrobiology03 medical and health sciencesAntibiotic resistancemedicinePharmacology (medical)mecAGeneral Pharmacology Toxicology and PharmaceuticsToxinStaphylococcal toxinsSCCmeclcsh:RM1-950Biofilmbiofilm activitylcsh:Therapeutics. Pharmacology030104 developmental biologyInfectious DiseasesStaphylococcus aureusStaphylococcus aureuStaphylococcal toxinAntibiotics
researchProduct

Negative Impact of Citral on Susceptibility of Pseudomonas aeruginosa to Antibiotics

2021

Essential oils (EOs) or their components are widely used by inhalation or nebulization to fight mild respiratory bacterial infections. However, their interaction with antibiotics is poorly known. In this study we evaluated the effects of citral, the main component of lemongrass oil, on in vitro susceptibility of Pseudomonas aeruginosa to antibiotics. Exposure of strain PA14 to subinhibitory concentrations of citral increased expression of operons encoding the multidrug efflux systems MexEF-OprN and MexXY/OprM, and bacterial resistance to anti-pseudomonal antibiotics including imipenem (twofold), gentamicin (eightfold), tobramycin (eightfold), ciprofloxacin (twofold), and colistin (≥128-fold…

0301 basic medicineMicrobiology (medical)antibiotic resistancemedicine.drug_class[SDV]Life Sciences [q-bio]030106 microbiologyAntibioticsmedicine.disease_causeCitralMicrobiologyMicrobiology03 medical and health scienceschemistry.chemical_compoundtobramycin-citral Schiff baseTobramycinmedicine[CHIM]Chemical Sciencesessential oilscitralOriginal ResearchPseudomonas aeruginosaChemistryAminoglycosidecolistin-citral Schiff baseSciences du Vivant [q-bio]/Microbiologie et Parasitologie[SDV.MP.BAC]Life Sciences [q-bio]/Microbiology and Parasitology/BacteriologyeffluxQR1-5023. Good health030104 developmental biology[SDV.SP.PHARMA] Life Sciences [q-bio]/Pharmaceutical sciences/PharmacologyPseudomonas aeruginosaColistin[SDV.SP.PHARMA]Life Sciences [q-bio]/Pharmaceutical sciences/PharmacologyGentamicinEfflux[SDV.MP.BAC] Life Sciences [q-bio]/Microbiology and Parasitology/Bacteriologymedicine.drugFrontiers in Microbiology
researchProduct